Skip To Main Content
Vivienne Raper on Muck Rack

Vivienne Raper

London
As seen in: The Wall Street Journal, Flipboard, Science Magazine, Ghost, Genetic Literacy Project, NewsBreak, Genetic Engineering & Biotechnology News, Aunt Minnie, Aunt Minnie Europe
Freelance medical, science & tech writer. Writes sci-fi. Analogue gamer. Home edder. Mum to two glorious neurodivergent kiddos. vivraper.bsky.social
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vivienne

Contact Vivienne, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Allogeneic CAR T Company Prepares to Widen Access to Patients

|
By Vivienne Raper
| Genetic Engineering & Biotechnology News Verified
Home Topics Bioprocessing Allogeneic CAR T Company Prepares to Widen Access to Patients CAR T cells attacking cancer cell. [Design Cells/Getty Images] A CAR T-cell therapy company using donor cells is planning to move to a pivotal Phase III clinical trial thanks to their genome editing strategies and optimization of their product, including choice of donors under 30.
Open in Who Shared Issue with article?

Seamless Integration in Gene Therapy Process Development

|
By Vivienne Raper
| Genetic Engineering & Biotechnology News Verified
The manufacturing question over adeno-associated viruses (AAV) for gene therapies has moved beyond whether a product can be made to whether it can be made consistently. That’s according to Forge Biologics, a contract manufacturer specializing in AAV production. According to Sumit Dutta, associate director of upstream process development at Forge Biologics, AAVs maturing as a technology means the industry should become more focused on how best to bring products to market.
Open in Who Shared Issue with article?

Capsid Experts Hope to Slash the Cost of Gene Therapies

|
By Vivienne Raper
| Genetic Engineering & Biotechnology News Verified
A company with expertise in capsid discovery say they have boosted adeno-associated virus (AAV) yields ten-fold compared to the industry standard. Affinia Therapeutics believes that, by adopting their methodical approach to AAV manufacturing, the industry could improve patient access to gene therapies by dramatically cutting costs.
Open in Who Shared Issue with article?
See all 289 articles